中药联合抗肿瘤血管生成药物治疗非小细胞肺癌的研究进展  

Progress in the Study of Traditional Chinese Medicine Combined with Antitumor Angiogenic Drugs in the Treatment of Non-small Cell Lung Cancer

作　　者：刘宝生 周秀丽 朱彦[3] 刘丽红[3] 于泽胜 王振华[1] LIU Baosheng;ZHOU Xiuli;ZHU Yan;LIU Lihong;YU Zesheng;WANG Zhenhua(Department of Clinical Pharmacy,Weifang Hospital of Traditional Chinese Medicine,Weifang 261000,China;Department of Clinical Pharmacy,Weifang People's Hospital,Weifang 261000,China;Institute of Information on Traditional Chinese Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China)

机构地区：[1]潍坊市中医院临床药学科,山东潍坊261000 [2]潍坊市人民医院临床药学科,山东潍坊261000 [3]中国中医科学院中医药信息研究所,北京100700

出　　处：《基层中医药》2024年第2期112-118,共7页Basic Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(82274684);潍坊市卫生健康委员会科研项目(WFWSJK-2022-279);潍坊市卫生健康委员会中医药科研项目[2022年(第4类)第50号];中国毒理学会临床毒理专项研究课题(CST2019CT307);潍坊市科技发展计划(软科学)(2022RKX066)。

摘　　要：非小细胞肺癌(NSCLC)是肺癌最为常见的一种病理类型,一半以上的患者确诊时即为进展期肺癌,患者生存期较短。抗肿瘤血管生成药物是目前治疗非小细胞肺癌的重要靶向药物,其临床疗效已获得临床认可,但仍存在耐药性及毒副作用不可耐受的局限性,而中药辨证论治及减毒增效的优点,可减轻药物的不良反应,并提高临床疗效,已成为中西医结合治疗非小细胞肺癌的重要方向。本文主要通过检索2010年1月—2023年6月中国知网、万方、维普及PubMed等数据库中的相关文献,总结近年来不同中药联合各类抗肿瘤血管生成药物治疗NSCLC的相关研究,试从不同角度探讨治疗NSCLC的新思路。Non-small cell lung cancer(NSCLC)is the most common pathological type of lung cancer,and more than half of the patients are diagnosed with progressive lung cancer,with a shorter survival period.Anti-tumor angiogenic drugs are important target drugs for the treatment of NSCLC,and their clinical efficacy has been clinically recognized.However,they still have the limitations of drug resistance and intolerable toxic side effects,whereas the advantages of traditional Chinese medicine(TCM)in identifying and treating the disease,reducing toxicity,and increasing efficacy can alleviate the adverse effects of the drugs and improve the clinical efficacy,which has become an important direction of traditional Chinese and western medicines in the treatment of NSCLC.This paper mainly searched the relevant literature in the databases of China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,and PubMed from January 2010 to June 2023 and summarized the relevant studies on different traditional Chinese medicines combined with various types of anti-tumor angiogenic drugs in the treatment of NSCLC in recent years,so as to explore the new ideas for the treatment of NSCLC from different perspectives.

关 键 词：非小细胞肺癌 中药 抗肿瘤血管生成药物 联合治疗 

分 类 号：R73[医药卫生—肿瘤]